|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [aranidipine results in increased expression of ABCA1 protein] |
CTD |
PMID:16306803 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]] |
CTD |
PMID:27743861 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of ABCB1 protein |
CTD |
PMID:12926078 PMID:23466342 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]] |
CTD |
PMID:26049102 PMID:27743861 PMID:31300867 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADCYAP1 protein results in increased expression of SELENOT mRNA] |
CTD |
PMID:18198219 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADM protein results in decreased activity of MAPK1 protein] |
CTD |
PMID:10374718 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADORA2B protein inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]] |
CTD |
PMID:35143882 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akna |
AT-hook transcription factor |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in decreased expression of AKNA mRNA] |
CTD |
PMID:29079362 |
|
NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions affects phosphorylation decreases activity |
ISO EXP |
SB 203580 inhibits the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the phosphorylation of AKT1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of AKT1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:10998351 PMID:17640974 PMID:39233265 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of CETP mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of CETP protein] |
CTD |
PMID:22056562 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein] |
CTD |
PMID:22056562 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [VIP protein results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein] |
CTD |
PMID:15967414 PMID:16888076 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:12164941 PMID:16671086 PMID:22188298 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of ATF3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of ATF3 protein] |
CTD |
PMID:25136830 PMID:30409902 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of and results in decreased phosphorylation of BAD protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [BAD protein binds to BCL2L1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of BAD protein |
CTD |
PMID:12629175 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [BAD protein binds to BCL2L1 protein] |
CTD |
PMID:12629175 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in decreased expression of BIRC5 protein] |
CTD |
PMID:18377872 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of BMP4 mRNA] |
CTD |
PMID:34070360 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein] |
CTD |
PMID:20067577 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:21873648 PMID:32115946 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CCL2] |
CTD |
PMID:11342529 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of CCND1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein] |
CTD |
PMID:17680988 PMID:22493441 PMID:26964897 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]] |
CTD |
PMID:27261088 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]] |
CTD |
PMID:27261088 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN1A mRNA] |
CTD |
PMID:16361081 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN2B mRNA] |
CTD |
PMID:16361081 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPB mRNA] |
CTD |
PMID:14684744 PMID:21220312 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions affects localization decreases activity |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Octanol results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of CFTR protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of CFTR protein |
CTD |
PMID:12606488 PMID:14744818 PMID:14967738 PMID:15763242 PMID:15994425 PMID:21724857 More...
|
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF2 protein] |
CTD |
PMID:26125464 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chi3l3 |
chitinase 3-like 3 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA] |
CTD |
PMID:27261088 |
|
NCBI chr 2:193,808,135...193,825,511
Ensembl chr 2:193,812,431...193,825,513
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]] |
CTD |
PMID:11576339 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein] |
CTD |
PMID:21177286 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]] |
CTD |
PMID:11576339 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased expression of CPT1A mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of CREB1 mRNA] [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(3-3,4-p-menthadien-(1,8)-yl)olivetol results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [alternariol results in increased expression of CREB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [O-1602 compound results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of CREB1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]] |
CTD |
PMID:10908723 PMID:12164941 PMID:15385614 PMID:15522277 PMID:16159392 PMID:16671086 PMID:17322281 PMID:17680988 PMID:18004999 PMID:18276108 PMID:19282384 PMID:19654912 PMID:21177760 PMID:24726522 PMID:30269738 PMID:30503586 PMID:30841431 PMID:30951808 PMID:33359577 PMID:34070360 PMID:37353053 PMID:39233265 More...
|
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sodium Oxybate results in increased phosphorylation of CREBBP protein] |
CTD |
PMID:16675135 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein] |
CTD |
PMID:33359577 |
|
NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:22493441 PMID:26964897 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [3',4'-dimethoxyflavone results in increased expression of CYP11B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22172629 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP19A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Water Pollutants, Chemical analog results in increased expression of CYP19A1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein] |
CTD |
PMID:19147701 PMID:20096755 PMID:20678559 PMID:21932247 PMID:28571770 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TNF protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] |
CTD |
PMID:20093341 PMID:25233930 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithocholic Acid results in increased activity of DIO2 protein] |
CTD |
PMID:19036883 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein] |
CTD |
PMID:14622123 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine] |
CTD |
PMID:14759557 PMID:15245872 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein] |
CTD |
PMID:15245872 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein] |
CTD |
PMID:15245872 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA] |
CTD |
PMID:22493441 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of EGR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 protein] |
CTD |
PMID:15621046 PMID:22174042 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ereg |
epiregulin |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA] |
CTD |
PMID:16888076 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA] |
CTD |
PMID:35908931 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:20360387 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein] |
CTD |
PMID:27261088 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dieldrin results in increased expression of FOS mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOS mRNA] |
CTD |
PMID:10864209 PMID:15179140 PMID:21177286 PMID:31068361 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA] |
CTD |
PMID:21177286 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL2 mRNA] |
CTD |
PMID:21177286 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Estradiol]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased secretion of Progesterone] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased phosphorylation of TSC2 protein] |
CTD |
PMID:15967414 PMID:17510244 PMID:18535249 PMID:21177760 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gast |
gastrin |
decreases secretion |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of GAST protein |
CTD |
PMID:19208342 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:26964897 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gcm1 |
glial cells missing transcription factor 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein] |
CTD |
PMID:16166624 |
|
NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in decreased expression of GH1 mRNA] |
CTD |
PMID:29079362 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22645130 PMID:37372083 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:24910983 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in decreased expression of and results in decreased activity of GPX1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [roflupram inhibits the reaction [Copper Sulfate results in decreased expression of GPX1 protein]] |
CTD |
PMID:24910983 PMID:37353053 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein] |
CTD |
PMID:14622123 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein] |
CTD |
PMID:20067577 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD protein] |
CTD |
PMID:37353053 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Caffeine results in increased phosphorylation of GSK3B protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:21229324 PMID:39233265 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Has2 |
hyaluronan synthase 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA] |
CTD |
PMID:21220312 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of HMOX1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [hexacyanoferrate III results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein] |
CTD |
PMID:15179140 PMID:16439612 PMID:19483313 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of HSD11B1 mRNA] |
CTD |
PMID:33581290 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Iloprost results in increased expression of ID1 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Ighe |
immunoglobulin heavy constant epsilon |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA] |
CTD |
PMID:12230500 |
|
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IKBKB mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Histamine results in increased expression of IL18 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL18 protein] |
CTD |
PMID:16723495 PMID:37353053 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of IL1B protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL1B protein] |
CTD |
PMID:23284918 PMID:29079362 PMID:37353053 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression decreases secretion |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL4 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL4 protein |
CTD |
PMID:11886533 PMID:12230500 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases expression decreases secretion |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL5 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL5 protein |
CTD |
PMID:11886533 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of IL6 protein] |
CTD |
PMID:23284918 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of PLIN2 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PLIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARGC1A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of UCP1 protein] |
CTD |
PMID:29288687 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IRS1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein] |
CTD |
PMID:21457779 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 PMID:18755854 PMID:21177286 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA] |
CTD |
PMID:21177286 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]] |
CTD |
PMID:16909339 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNH2 protein] |
CTD |
PMID:22853924 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNJ2 protein] |
CTD |
PMID:22853924 |
|
NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]] |
CTD |
PMID:16909339 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [KNG1 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:15750287 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lep |
leptin |
multiple interactions decreases response to substance |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CCL2]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased susceptibility to LEP protein |
CTD |
PMID:11342529 PMID:19254925 PMID:28571770 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PGR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of TNFAIP6 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased secretion of Progesterone] |
CTD |
PMID:15967414 PMID:21220312 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Thioctic Acid results in increased phosphorylation of LIPE protein] |
CTD |
PMID:22941773 PMID:23362264 PMID:29288687 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADM protein results in decreased activity of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:10374718 PMID:11675405 PMID:12657697 PMID:16099847 PMID:16439612 PMID:16671086 PMID:17322281 PMID:18004999 PMID:20860660 PMID:21177760 PMID:25044243 PMID:37372083 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Ro 31-8425 inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ro 31-8425 promotes the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:11675405 PMID:12657697 PMID:15385614 PMID:16099847 PMID:16439612 PMID:16671086 PMID:17322281 PMID:18004999 PMID:20860660 PMID:21177760 PMID:25044243 PMID:37372083 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [isosakuranetin results in increased expression of MITF protein] |
CTD |
PMID:26524968 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]] |
CTD |
PMID:19053045 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of MMP9 mRNA] |
CTD |
PMID:24929186 PMID:29079362 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein] |
CTD |
PMID:27261088 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA] |
CTD |
PMID:26964897 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh4 |
myosin heavy chain 4 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 protein] |
CTD |
PMID:21374593 |
|
NCBI chr10:51,923,149...51,946,297
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Phenylephrine results in increased expression of MYH7 mRNA] |
CTD |
PMID:18851973 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myog |
myogenin |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG protein] |
CTD |
PMID:21374593 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of NFE2L2 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of NFE2L2 protein] |
CTD |
PMID:29870751 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of NLRP3 protein] |
CTD |
PMID:37353053 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Mevinphos results in increased expression of NOS1 protein] |
CTD |
PMID:15245872 PMID:17438462 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:18851973 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of NQO1 mRNA] |
CTD |
PMID:37353053 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein] |
CTD |
PMID:18787026 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]] |
CTD |
PMID:27743861 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cadmium acetate results in increased expression of NR4A1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased expression of NR4A1 mRNA] |
CTD |
PMID:12021184 PMID:15016657 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein] |
CTD |
PMID:22188298 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dimaprit results in increased expression of NTF3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Histamine results in increased expression of NTF3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Neurotransmitter Agents results in increased expression of NTF3 protein] |
CTD |
PMID:19854260 PMID:21276809 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of PGR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PGR mRNA] |
CTD |
PMID:21220312 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pink1 |
PTEN induced kinase 1 |
decreases expression multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PINK1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of PINK1 protein] |
CTD |
PMID:29870751 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [PLD1 protein promotes the reaction [cobaltous chloride results in increased expression of PTGS2 protein]] |
CTD |
PMID:17640750 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PLIN1 protein] |
CTD |
PMID:29288687 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of PLIN2 protein |
CTD |
PMID:29288687 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pln |
phospholamban |
decreases phosphorylation |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased phosphorylation of PLN protein |
CTD |
PMID:27495954 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein] |
CTD |
PMID:29288687 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
decreases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PNPLA6 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PNPLA6 protein |
CTD |
PMID:20380879 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [diethyl phosphate results in decreased secretion of POMC protein] |
CTD |
PMID:35777568 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARGC1A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 PMID:29288687 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:19167487 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of PRKACA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of PRKACA protein] |
CTD |
PMID:19053045 PMID:37353053 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
decreases phosphorylation multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased phosphorylation of PRKAR2A protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [resveratrol results in increased phosphorylation of PRKAR2A protein] |
CTD |
PMID:25943029 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkca |
protein kinase C, alpha |
decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of PRKCA protein |
CTD |
PMID:16361081 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:22188298 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [PLD1 protein promotes the reaction [cobaltous chloride results in increased expression of PTGS2 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:17407152 PMID:17640750 PMID:18938131 PMID:19063610 PMID:19147701 PMID:21220312 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [PTH protein results in decreased uptake of Phosphates] |
CTD |
PMID:27432882 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADORA2B protein inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]] |
CTD |
PMID:22188298 PMID:35143882 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rnf187 |
ring finger protein 187 |
decreases stability |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased stability of RNF187 protein |
CTD |
PMID:25851810 |
|
NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157
|
|
G |
Rock2 |
Rho-associated coiled-coil containing protein kinase 2 |
decreases activity |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of ROCK2 protein |
CTD |
PMID:10998351 |
|
NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA3 protein |
CTD |
PMID:10998351 |
|
NCBI chr X:35,517,306...35,623,296
Ensembl chr X:35,517,306...35,623,207
|
|
G |
Rps6ka5 |
ribosomal protein S6 kinase A5 |
decreases activity |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA5 protein |
CTD |
PMID:10998351 PMID:15522277 PMID:18377872 |
|
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KB1 protein |
CTD |
PMID:10998351 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Ryr2 |
ryanodine receptor 2 |
decreases phosphorylation |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased phosphorylation of RYR2 protein |
CTD |
PMID:27495954 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of S100B protein] |
CTD |
PMID:23284918 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of SCARB1 mRNA] |
CTD |
PMID:33581290 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sct |
secretin |
multiple interactions decreases activity |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of SCT protein |
CTD |
PMID:10880878 PMID:22194894 |
|
NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658
|
|
G |
Selenot |
selenoprotein T |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADCYAP1 protein results in increased expression of SELENOT mRNA] |
CTD |
PMID:18198219 |
|
NCBI chr 2:142,804,387...142,821,438
Ensembl chr 2:142,804,405...142,821,427
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of SGK1 protein |
CTD |
PMID:10998351 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Si |
sucrase-isomaltase |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with TNF protein] results in decreased expression of SIRT1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein] |
CTD |
PMID:24145604 PMID:25943029 PMID:30409902 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]] |
CTD |
PMID:27743861 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 protein] |
CTD |
PMID:22645130 PMID:24782323 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased expression of SLC2A3 protein] |
CTD |
PMID:24726522 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SLC2A4 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] |
CTD |
PMID:12820898 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in decreased expression of and results in decreased activity of SOD1 protein] |
CTD |
PMID:24910983 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of SOD2 mRNA] |
CTD |
PMID:20685861 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] |
CTD |
PMID:20453393 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF1 protein] |
CTD |
PMID:26125464 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF2 protein] |
CTD |
PMID:26125464 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO EXP |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of STAR mRNA] |
CTD |
PMID:18755854 PMID:18787026 PMID:19282384 PMID:19822634 PMID:23362264 PMID:33359577 PMID:33581290 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:22493441 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [5-methyltetrahydrofolate inhibits the reaction [Palmitic Acid results in decreased phosphorylation of STK11 protein]] |
CTD |
PMID:26400185 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [KNG1 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:15750287 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] |
CTD |
PMID:22552774 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNH2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNJ2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN2B mRNA] |
CTD |
PMID:11576339 PMID:16361081 PMID:22853924 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
EXP |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [HU 211 results in decreased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nicotine results in increased expression of TH mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of TH mRNA |
CTD |
PMID:18992715 PMID:29246838 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with TNF protein] results in decreased expression of SIRT1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dieldrin results in increased expression of TNF mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline results in decreased expression of TNF mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of TNF protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TNF protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]] |
CTD |
PMID:11675405 PMID:17407152 PMID:23284918 PMID:24145604 PMID:25233930 PMID:31068361 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFAIP6 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of TNFAIP6 mRNA] |
CTD |
PMID:21220312 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tph2 |
tryptophan hydroxylase 2 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sertraline results in increased expression of TPH2 mRNA] |
CTD |
PMID:11901216 |
|
NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium] |
CTD |
PMID:21453681 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tsc2 |
TSC complex subunit 2 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased phosphorylation of TSC2 protein] |
CTD |
PMID:17510244 |
|
NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]] |
CTD |
PMID:20453393 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Tyr |
tyrosinase |
multiple interactions decreases activity |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [scoparone results in increased expression of TYR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of TYR protein |
CTD |
PMID:17049123 PMID:30849679 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of UCP1 protein] |
CTD |
PMID:12414803 PMID:29288687 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of VASP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [N(6)-benzoyl-cyclic AMP results in increased phosphorylation of VASP protein] |
CTD |
PMID:22363678 PMID:32409581 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 PMID:19063610 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [VIP protein results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
G |
Wnt3a |
Wnt family member 3A |
multiple interactions |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of CREB1 mRNA] |
CTD |
PMID:34070360 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression decreases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased expression of XIAP protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of XIAP mRNA |
CTD |
PMID:21255191 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|